Valganciclovir
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01610 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 19 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | rheumatoid arthritis | KG + DL |
| 2 | bronchitis | KG + DL |
| 3 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 4 | brachydactyly-syndactyly syndrome | KG + DL |
| 5 | laryngotracheitis | KG + DL |
| 6 | osteoarthritis susceptibility | KG + DL |
| 7 | trigeminal autonomic cephalalgia | KG + DL |
| 8 | headache disorder | KG + DL |
| 9 | tendinitis | KG + DL |
| 10 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 11 | Lyme disease | KG + DL |
| 12 | idiopathic granulomatous myositis | KG + DL |
| 13 | myositis fibrosa | KG + DL |
| 14 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 15 | fibromyalgia | KG + DL |
| 16 | diabetic nephropathy | KG + DL |
| 17 | sclerosing cholangitis | KG + DL |
| 18 | bronchial neoplasm (disease) | KG + DL |
| 19 | inclusion body myositis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.